Of the HRDetect+ve cancers, 74%(14/19) had a detectable underlying mutation of BRCA1/2 and PALB2 or gene promoter hypermethylation of BRCA1 or RAD51C. None of the eight HRDetect−ve cancers had an underlying genetic/epigenetic defect (p = 0.0005, Fisher’s exact test; Fig. 2a). The gene discussed is PALB2; the disease is cancer.